Pancreatic cancer researchers at Thomas Jefferson University have shown, for the first time, that blocking a receptor of a key hormone in the renin-angiotensin system (RAS) reduces cancer cell growth by activating the enzyme AMPK to inhibit fatty acid synthase, the ingredients to support cell division. With that, a new chemopreventive agent that inhibits the angiotensin II type 2 receptor never before thought to play a role in tumor growth could be developed to help treat one of the fastest-moving cancers that has a 5-year survival rate of only 5 percent. Hwyda Arafat, M.D., Ph.D...
More...
More...